Glaucoma, Open-Angle
Pipeline by Development Stage
Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.
Key Trends
- Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
- Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
- Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape
Career Verdict
Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LUMIGAN (Bimatoprost) | AbbVie | $697M | 19% | LOE_APPROACHING | Declining | |
| 2 | OXERVATE (Cenegermin-BKBJ) | Unspecified | $493M | 13% | PEAK | Stable | |
| 3 | XIIDRA (Lifitegrast) | Bausch + Lomb | $473M | 13% | PEAK | Stable | 7.6yr |
| 4 | INLYTA (Axitinib) | Pfizer | $467M | 13% | PEAK | Growing | 11.2yr |
| 5 | HUMIRA (Adalimumab) | AbbVie | $258M | 7% | LOE_APPROACHING | Declining |
Drug Class Breakdown
mature, losing exclusivity
peak growth in corneal disease
sustained peak sales
expanding in retinal indications
mature, multiple LOE approaching
mature, losing exclusivity
mature immunology approach
Career Outlook
StableOphthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.
Breaking In
Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.
For Experienced Professionals
Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.
In-Demand Skills
Best For
Hiring Landscape
Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.
Top Hiring Companies
By Department
Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.
On Market (2)
Approved therapies currently available
Competitive Landscape
15 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 45 trials with date data
Clinical Trials (47)
Total enrollment: 13,573 patients across 47 trials
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
Use of Methazolamide to Lower Intraocular Pressure
Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
Performance of the Travoprost Intraocular Implant
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension
H-1337 Ophthalmic Solution Phase 1/2
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery
Post-Market Study of Alcon Intraocular Lenses
Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)
A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma
Safety and Efficacy of an Ab Interno Gelatin Stent (XEN63) With or Without Mitomycin C
Keratometric Change After XEN, Trabeculectomy and Tube Shunts
iStent Inject New Enrollment Post-Approval Study
A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma
iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
MINIject in Patients With Open Angle Glaucoma Using Single Operator Delivery Tool
MINIject Glaucoma Implant in European Patients
Sensing Contact Lens-based Device for 24-hour Monitoring of Intraocular Pressure
Investigation of the iStent Inject® Devices in Open-Angle Glaucoma
A Comparison of Cataract Surgery Alone and Cataract Surgery With iStent
A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent Supra
The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
Safety and Efficacy of Combigan® Ophthalmic Solution in Korea
Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
Related Jobs in Ophthalmology
AI Product Manager
Sr Engineer II, Machine Learning
Senior Quality Engineer
Research Associate/Senior Research Associate, In Vivo Pharmacology
Senior Manager, Global Logistics
Senior Manufacturing Engineer (Laser Welding)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.